Oramorph (Morphine Sulfate)

Oramorph is an opioid analgesic that acts on the central nervous system to relieve pain.

• Acute postoperative pain: provides effective relief after surgical procedures.
• Cancer‑related pain: helps manage persistent pain associated with malignant disease.
• Severe chronic pain: reduces pain intensity in conditions such as advanced osteoarthritis when other treatments fail.

• Morphine sulfate binds to μ‑opioid receptors in the central nervous system, mimicking endogenous opioids. This activation inhibits the release of excitatory neurotransmitters, reduces neuronal excitability, and diminishes the perception of pain signals, producing analgesia.

Morphine sulfate may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects

• Nausea and vomiting
• Constipation
• Drowsiness or sedation
• Dry mouth
• Sweating
• Itching (pruritus)

Serious or Rare Side Effects

• Respiratory depression
• Severe hypotension
• Bradycardia
• Hallucinations or delirium
• Severe allergic reactions (anaphylaxis)
• Dependence, tolerance and withdrawal symptoms

When using Oramorph, careful monitoring and adherence to safety guidelines are essential.

• Assess patient’s history of substance use: review risk of abuse and dependence.
• Adjust dose for renal or hepatic impairment: use lower initial doses and titrate cautiously.
• Avoid concomitant central nervous system depressants: monitor for enhanced sedation.
• Monitor respiratory function: watch for signs of respiratory depression, especially after dose changes.
• Educate patients on proper use and storage: emphasize that the medication is for oral use only and should not be shared.
• Store at below 25°C: keep in the original packaging, protect from moisture and light.

• Morphine sulfate can interact with several drug classes, altering its efficacy or safety profile.
• Major Interactions (Avoid):
• - C‑ ​       ​  ​  ​   ​  ​  ​   ​  ​   ​  ​  ​  ​   ​  C  ​  ​  ​  ​
• Moderate Interactions (Monitor Closely):
• - C  
• - C 
• - C 
• - C 
• - C